Prevalence of RV dysfunction in patients under cardiotoxic chemoterapy: a preliminary analysis

Abstract Background Chemotherapy-induced cardiotoxicity is a serious complication often leading to heart failure. While the left ventricle (LV) has been thoroughly implicated in this process, data scarce on right ventricular (RV) function following cardiotoxic chemotherapies. Our goal was determine prevalence and clinical significance of RV dysfunction cohort patients who had received these drugs. Methodology Single-center retrospective study cancer performing 2D transthoracic echocardiogram between January 2020 December 2021. Those previously exposed anthracyclines and/or anti-HER2 agents (≥6 months prior echocardiogram) were included. Patients with known coronary artery disease or cardiomyopathy excluded. LV assessed through ejection fraction (LVEF) global longitudinal strain (GLS). defined as per ESMO guidelines. considered abnormal if criteria met: tricuspid annular plane systolic excursion (TAPSE) <17 mm, peak velocity annulus by pulsed wave TDI (S'VD) <12 cm/s, area change (FAC) <35% mean free wall (FWLS) >−20%. Results Forty included (58±13 years; 95% female; 93% breast cancer; 30%, 20% 50% treated anthracyclines, both, respectively). Mean LVEF GLS 56±7% −17±3%. Overall, 13 current cardiotoxicity. documented 15 (38%) (7 [18%] isolated dysfunction), most detected FWLS (14 [35%], 7 [18%], 6 [15%] 5 [13%] FWLS, TAPSE, FAC S'VD, respectively) – Figure 1. Seven (18%) one patient (3%) ≥2 ≥3 parameters. more symptomatic (NYHA class ≥2: 53% vs. 16%; p=0.013), higher NT-proBNP levels (516 [204–2400] 66 [46–191] pg/mL; p=0.003) (62% 26%, p=0.029); pulmonary pressures similar both groups. Conclusion In our anti-neoplastic drugs, observed two out every five patients, associated worse symptoms levels. This suggests that may be common clinically impactful those under Funding Acknowledgement Type funding sources: None.